Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer

Gastroenterology(2020)10.1053/j.gastro.2020.09.043Source: DataRank Database

Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer is a research paper published in Gastroenterology (2020). On theSindex it has a DataRank of 3.6. It has been cited 174 times, with 134 citing works in its 1-hop citation network.

N/A

3.6DataRank · unranked

Scored on demand from live citation data

Open Access174 citations · 134 citing works in its network

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (59 grants)OA: hybridTopics (72)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 22%Citation Network 78%

Base Score Contribution

0.775

From this paper's citation signal

Citation Network Contribution

2.8

From 98 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 134 citers.

Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study
British journal of surgery202228 citations28 referencesContributes 0.120
Identification of treatment‐induced vulnerabilities in pancreatic cancer patients using functional model systems
EMBO Molecular Medicine202239 citations34 referencesContributes 0.108
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Nature Communications202169 citations44 referencesContributes 0.097
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Molecular Cancer Therapeutics202188 citations51 referencesContributes 0.088
hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma
Molecular Cancer202355 citations48 referencesContributes 0.084

Authors (83)

Rosanna Upstill‐Goddard ORCID,Viola Paulus-Hock ORCID,Clara Paris,Eirini-Maria Lampraki ORCID,Eloïse Dray ORCID

Live enrichment

PubMed:33039466 PMC:PMC8167930

Associazione Italiana per la Ricerca sul Cancro

Grant: 12182

Cancer Institute NSW

Grant: 06/ECF/1-24

Cancer Institute NSW

Grant: 06/RSA/1-05

Cancer Institute NSW

Grant: 07/CDF/1-03

Cancer Institute NSW

Grant: 07/CDF/1-28

Cancer Institute NSW

Grant: 08/RSA/1-15

Cancer Institute NSW

Grant: 09/CDF/2-40

Cancer Institute NSW

Grant: 09/RIG/1-02

Cancer Institute NSW

Grant: 10/CDF/2-26,10/FRL/2-03

Cancer Institute NSW

Grant: 10/CRF/1-01

Cancer Institute NSW

Grant: 10/ECF/2-26

Cancer Institute NSW

Grant: 10/TPG/1-04

Cancer Institute NSW

Grant: 11/CDF/3-26

Cancer Institute NSW

Grant: 11/REG/1-10

Wellcome Trust

Grant: 103721/Z/14/Z

National Institutes of Health

Grant: 5R01CA150190-07

Targeting Pancreatic Cancer Using Peptide Chemistry: From Bench to Bedside

National Institutes of Health

Grant: CA62924

National Institutes of Health

Grant: P50 CA102701

Cancer Research UK

Grant: C596/A20921

Cancer Research UK

Grant: 25714

Cancer Research UK

Grant: 27820

Cancer Research UK

Grant: 29996

NCI NIH HHS

Grant: P50 CA062924

NCI NIH HHS

Grant: R01 CA150190

Cancer Research UK

Grant: 30322

Cancer Research UK

Grant: A23526

Cancer Research UK

Grant: C596/A18076

NCI NIH HHS

Grant: P30 CA045508

Cancer Research UK

Grant: C29717/A18484

Cancer Research UK

Grant: 25813

Cancer Research UK

Grant: 25407

Cancer Research UK

Grant: C29717/A17263

NCI NIH HHS

Grant: P30 CA015083

Cancer Research UK

Grant: 16354

Cancer Research UK

Grant: 21139

Cancer Research UK

Grant: 23526

Cancer Research UK

Grant: 25233

National Health and Medical Research Council (NHMRC)

Grant: 535903

Molecular markers of phenotype, therapeutic responsiveness and prognosis in human cancers.

National Health and Medical Research Council (NHMRC)

Grant: 631701

International Cancer Genome Consortium

National Institutes of Health

Grant: 5P50CA062924-25

SPORE in Gastrointestinal Cancers

National Institutes of Health

Grant: 5P50CA102701-10

Hedgehog EGF Pathway Interaction: Novel Multi-Target Therapy Pancreatic Cancer

National Health and Medical Research Council (NHMRC)

Grant: 427601

Research Fellowship - Grant ID:427601

European Commission

Grant: 602783

Integrative Analysis of Gene Functions in Cellular and Animal Models of Pancreatic Cancer

Wellcome Trust

Grant: 103721

Defining Platinum and PARP inhibitor Responsive Molecular Phenotypes of Pancreatic Cancer.

Wellcome Trust

Petre Foundation

Queensland Government

Royal College of Physicians

Australian Cancer Research Foundation

Ontario Institute for Cancer Research

American Association for Cancer Research

Royal College of Pathologists of Australasia

Garvan Institute of Medical Research

R.T. Hall Trust

Royal College of Surgeons of Edinburgh

University of Queensland

Howat Foundation

Cancer Council NSW

Wellcome Trust

hybridLicense: cc-by

publisherhttp://www.gastrojournal.org/article/S001650852035229X/pdf

publisherhttps://api.elsevier.com/content/article/PII:S001650852035229X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S001650852035229X?httpAccept=text/plain

repositoryhttp://eprints.gla.ac.uk/223681/3/223681.pdf

repositoryhttps://unsworks.unsw.edu.au/bitstreams/51abad67-fb76-425b-aea8-e1f5608b377a/download

Fields of Study

0301 basic medicine03 medical and health sciencesAdenocarcinomaBiomarkersCell Culture TechniquesCell Line, TumorDNA DamageDNA RepairDNA ReplicationHumansMolecular Targeted TherapyOrganoidsPancreatic NeoplasmsXenograft Model Antitumor Assays

MeSH Terms

OrganoidsCell Line, TumorHumansAdenocarcinomaPancreatic NeoplasmsDNA DamageCell Culture TechniquesXenograft Model Antitumor AssaysDNA RepairDNA ReplicationMolecular Targeted TherapyBiomarkers

Keywords

Pancreatic cancerPersonalized MedicineDna Damage ResponseReplication StressGlasgow Precision Oncology LaboratoryDNA RepairCell Culture Techniques200199 - Clinical health not elsewhere classified32 Biomedical and Clinical Sciencesanzsrc-for: 1103 Clinical Sciences2.1 Biological and endogenous factorsMolecular Targeted TherapyPrecision MedicineCancerOriginal Research429999 - Other health sciences not elsewhere classifiedTumor3 Good Health and Well BeingOrganoids5.1 Pharmaceuticalsanzsrc-for: 3202 Clinical sciencesDNA Replication570anzsrc-for: 1114 Paediatrics and Reproductive Medicine610anzsrc-for: 1109 NeurosciencesAdenocarcinomaCell LineRare Diseasesanzsrc-for: 32 Biomedical and Clinical SciencesClinical ResearchAustralian Pancreatic Cancer Genome InitiativeCell Line, TumorGeneticsHumansanzsrc-for: 3211 Oncology and CarcinogenesisDNA Damage Response; Pancreatic Cancer; Personalized Medicine; Replication Stressanzsrc-for: 3210 Nutrition and dietetics3211 Oncology and CarcinogenesisXenograft Model Antitumor Assays4.1 Discovery and preclinical testing of markers and technologiesPancreatic NeoplasmsOrphan DrugDigestive DiseasesBiomarkersDNA Damage

Sustainable Development Goals

SDG 3: 3. Good health